How Fast Does Geographic Atrophy Progress?
Geographic Atrophy Progression at a Glance
Most of the time, this damage spreads slowly. Across study groups, the average growth was about 0.53 to 2.6 square millimeters a year, with a middle value close to 1.781. A square millimeter is about the size of a pinhead. So the change you can measure on a scan takes years, not weeks.
The pace differs from person to person. Some eyes stay steady a long time. Others move faster. Your eye doctor can measure your own pace from two scans a year apart, and that number means more than any average.
Geographic atrophy is a late form of dry macular degeneration, in which small patches of the light-sensing layer at the back of the eye thin out and stop working. It is the late stage of dry age-related macular degeneration, and dry forms account for about 85 of every 100 people who have macular degeneration2. What grows is the area of those patches, measured in square millimeters on a retinal scan.
That matters, because the number your doctor tracks and the thing you care about do not move in step. A patch can widen for years while your reading vision stays usable, as long as the center is spared.
Three things follow from a slow, measurable disease. Keep your scheduled retina appointments so the pace can be tracked. Check each eye on its own at home, so a change gets noticed early. And ask to see your own two scans side by side.
What Geographic Atrophy Is and Who Develops It
Under the retina sits a support layer, the retinal pigment epithelium, that feeds and cleans the light-sensing cells above it. In geographic atrophy, patches of that layer and the cells it serves waste away, leaving sharply outlined areas that no longer signal the brain. Those areas read as blank or dim spots rather than black holes, because the brain fills in around them.
The plain-word version: nothing is growing, bleeding or infected. This is a slow wearing-away of tissue. Why it starts is not fully settled, and age is the dominant risk, but genetic variants, including ones in the ARMS2 and complement genes, are linked both to developing the atrophy and to how fast it grows3.
In populations of European ancestry, geographic atrophy is found in roughly 7 of every 1,000 people at age 70, about 29 of every 1,000 at age 80, and about 113 of every 1,000 at age 904. Age is the strongest driver, which is why it is often found on a routine exam before anyone has symptoms.
This is not rare at older ages, and it does not mean your sight is about to go. It means you belong in regular retinal care.
Geographic atrophy typically begins next to the fovea, the pinpoint center of sharp vision, and may later spread into it2. This off-center pattern is why so many people have measurable damage and near-normal chart vision at the same time.
It also explains a common frustration: words drop out at the edge of a line, or a face looks patchy, yet the eye chart score is fine. Both can be true, and both belong in the conversation.
How Fast the Atrophy Area Actually Grows
The most quoted figures come from pooling studies. Reported growth across study groups ranged from 0.53 to 2.6 square millimeters a year, with a median near 1.78, and the features that repeatedly predicted a faster pace were the starting size of the patch, its location, whether it was in several pieces, its pattern on a special retinal photograph, and the state of the other eye1.
Read that range as a spread, not a countdown. Your own rate is a measurement, not a prediction.
Bigger patches tend to widen faster, which is useful for planning follow-up. Grouped by starting size, atrophy under 1.3 square millimeters grew about 0.8 square millimeters a year, patches of 1.3 to 8.3 square millimeters grew about 2.1, and patches larger than 8.3 square millimeters grew about 3.03.
| Starting size of the patch | Typical growth per year | What that tends to mean |
|---|---|---|
| Under 1.3 square millimeters | About 0.8 square millimeters | Slowest group; often no symptoms yet |
| 1.3 to 8.3 square millimeters | About 2.1 square millimeters | The most common group at diagnosis |
| Larger than 8.3 square millimeters | About 3.0 square millimeters | Faster spread; closer follow-up is usual |
These are group averages, not a schedule for your eye. Direction matters too: atrophy expands considerably faster away from the fovea than toward it, and both the pattern seen on a fundus autofluorescence photograph and the presence of reticular pseudodrusen, a specific deposit pattern, are linked with faster enlargement3. That is part of why central reading vision often lasts longer than the raw numbers suggest.
Central vision is what reading and faces depend on, so this is the real question. Typically, the interval from atrophy that spares the center to atrophy that involves the center is around 3 years4. In one large study, among eyes whose atrophy started off-center, 57 of every 100 had the center involved within 4 years5.
Turned around, a sizable minority still had a spared center after 4 years. And even once the center is involved, side vision remains, which is what mobility runs on.
What Makes Geographic Atrophy Progress Faster or Slower
Most of what predicts pace is visible on your scans, not in your habits. In a large study within a clinical trial, faster enlargement went with atrophy that spared the center, atrophy in several separate pieces, a middling starting size, and atrophy in both eyes5.
Studies do not agree perfectly on which starting size grows fastest. What they agree on is that none of these features is something you caused, and none settles your outcome; they mainly shape how closely you are watched.
The two eyes tend to behave alike. Involvement of both eyes was one of the features linked with faster enlargement5, and the state of the fellow eye is one of the repeatedly confirmed predictors of how quickly atrophy grows1.
So check each eye separately at home: a good eye covers for a weaker one so well that a change goes unnoticed for months.
Risk of macular degeneration rises with age above 55, smoking, a family history of the disease, and white ancestry6. Age, family and ancestry are fixed. Smoking is not, and guidelines advise that patients who smoke be counseled to stop7.
There is an honest wrinkle here. In that same large study, neither the study supplement assignment nor smoking status significantly changed how fast existing atrophy enlarged5. Stopping smoking still matters for your eyes and your health; it is just not a lever shown to slow a patch that already exists.
Symptoms and Warning Signs as the Atrophy Advances
Early atrophy is often silent, especially when it sits off-center and the other eye is healthy. As dry macular degeneration advances, common complaints include trouble reading in dim light, colors looking less intense, difficulty with night driving, and dark or blurry areas in the middle of vision2.
If you recognize yourself in that list, report it at your next visit rather than adjusting around it. Better lighting, stronger reading glasses and magnification often restore a lot of function.
People rarely describe a black patch. More often letters drop out of the middle of a word, a face looks smudged where the eyes should be, or a spot seems to move as you look around, because the missing area sits inside your vision rather than at its edge.
Even at this stage, sight is not gone. Macular degeneration is a leading cause of vision loss in older adults, but it does not cause complete blindness6. Side vision stays, and it carries walking and much of daily independence.
One change does not fit the slow pattern: a sudden bend or wave in straight lines, or a new blurred patch that appears over days. Straight lines that start to look wavy are a warning sign of late macular degeneration and should be reported to an eye doctor right away6.
The reason is that wet macular degeneration, in which leaky new vessels grow under the retina, can develop on top of atrophy and moves in days rather than years. Catching it early is associated with better long-term vision than catching it late7, which is why this symptom gets its own rule.
How Your Eye Doctor Measures Your Progression
Tracking pace needs pictures, not just an eye chart. Progression in research has been assessed mainly with color photographs of the retina and with fundus autofluorescence imaging, which makes the atrophy edges stand out1. Optical coherence tomography, a scan that shows the retina in cross section, is also part of routine macular degeneration care7.
All are quick, painless and done in the clinic. Your team compares the size and shape of the patches against earlier images, checks how close the edge is to the center, and looks for fluid that would suggest the wet form.
This surprises people. In a long-running series of patients, vision at the start varied widely for the same amount of atrophy, largely depending on whether the fovea was spared8. Chart acuity measures one pinpoint of retina, and the growing patch may not have reached it yet.
So a stable acuity is reassuring, but it is not proof that nothing is changing. That is why imaging, not just the letters on the wall, sets your follow-up plan.
What Can Slow Geographic Atrophy Down
Two medicines, pegcetacoplan and avacincaptad pegol, are now available in the United States for geographic atrophy, given as injections into the eye every one to two months2. Both damp down part of the immune system, called the complement system, that appears to drive the tissue loss9.
They are the first treatments aimed at the atrophy itself rather than at its consequences. Whether one suits you is a discussion with a retina specialist about your lesion, your other eye, and frequent visits.
The size of the effect is modest. In the phase 3 trials, these injections slowed the growth of the atrophy area by roughly one eighth to one quarter compared with dummy injections over one to two years, but did not improve the vision measures the trials set out to test; in the pegcetacoplan trials, average acuity loss over two years was about 7 letters with dummy injections and about 8 to 9 letters with treatment9.
In plain terms, they slow the map, and so far have not been shown to change what you can read. Reported harms include new wet macular degeneration, inflammation inside the eye, and damage to the optic nerve from poor blood supply9. That balance makes this a genuine decision, not an automatic yes.
Antioxidant vitamin and mineral supplements of the type studied in AREDS and AREDS2 are considered for people who have reached the intermediate or advanced stage in at least one eye7, and supplements of this kind may delay progression of dry macular degeneration2. Ask your doctor whether the formula fits you: the studied benefit was slowing progression at earlier stages, not shrinking atrophy that already exists.
Alongside that, not smoking, a diet with leafy greens and fish, and control of blood pressure and cholesterol are the general measures recommended for macular degeneration6. They are worth doing, without being sold as a way to stop a patch that has already formed.
Referral for vision rehabilitation is an important part of macular degeneration care7, and these services help people with late dry macular degeneration make the most of remaining sight6. Low-vision therapy is part of routine care for this condition2.
Task lighting, magnifiers and high-contrast displays work best when introduced early, while you still have vision to build habits around.
Risks, Complications and a Realistic Outlook
This is the most important complication to know about, because it moves fast and it is treatable. Among eyes that newly developed geographic atrophy in one large study, 29 of every 100 went on to develop wet macular degeneration within 4 years5.
Read that alongside its mirror image: about 71 of every 100 did not. The practical response is a plan, not worry: home monitoring plus a same-week call if straight lines change.
In a series of 123 patients followed for a median of 3 years, 31 of every 100 study eyes lost three lines of vision by 2 years and 53 of every 100 had lost three lines by 4 years; among eyes that began with reasonably good vision, 27 of every 100 had dropped to 20/200 or worse by 4 years8.
Those are meaningful losses, and not universal: roughly half of eyes had not lost three lines at 4 years. Numbers like these describe groups, never one person's next year.
Geographic atrophy tends to worsen gradually, and no treatment restores tissue that is already gone. What is realistic is a slower map with treatment for some people, early detection of the wet form, and vision support that keeps reading, cooking and getting around workable for years.
Most people with this diagnosis keep functioning independently for a long time. Planning around that, rather than around a worst case, is more accurate and more useful.
When to Call Your Eye Doctor About a Change
Slow change is expected. A fast change is not, and needs prompt attention. Call your eye doctor without delay if you notice any of these in either eye:
- Straight lines, door frames or text that suddenly look bent or wavy
- A new blurred or blank area in the center of your vision that appeared over hours or days
- A sudden drop in how well one eye reads, when you cover the other eye
- A new dark spot that grows noticeably over a week or two
- New distortion in an eye that was stable at your last visit
Guidelines advise that people at increased risk of advanced macular degeneration be taught to monitor each eye at home and to report new symptoms promptly to an ophthalmologist, who can confirm whether new leaky vessels are the cause and start treatment; detecting that form earlier is associated on average with better long-term vision than detecting it late7. Being checked and reassured costs one appointment, so make the call.
Between those calls, the plan is simple. Home monitoring uses an Amsler grid, a square grid with a central dot, or an equivalent home test, checked with one eye at a time7. Your retina clinic sets the interval between visits.
Fix the home check to something you already do daily, such as morning coffee. A check you perform beats a better one you skip.
Geographic atrophy is managed by a retina specialist, an ophthalmologist with extra training in diseases at the back of the eye, usually alongside your regular optometrist for glasses and general eye care. A low-vision optometrist or occupational therapist joins in when daily tasks get harder.
If you have been diagnosed but have not seen a retina specialist, ask for that referral. Measuring your own rate of change is the step everything else depends on.
Common Questions About How Fast Geographic Atrophy Progresses
Nobody can tell you your personal pace from averages, but your own scans can estimate it. Across study groups, average growth ran from roughly 0.5 to 2.6 square millimeters a year, with a midpoint near 1.8. Your rate depends on the size of the patch now, whether it is in several pieces, and where it sits relative to the center. Two scans a year apart give your doctor a measured rate.
On average, atrophy that spares the center takes around 3 years to involve it, and in one large study 57 of every 100 off-center lesions had reached the center by 4 years. That leaves a substantial group still spared at 4 years. Position matters more than size, since a patch close to the center has less distance to travel. Ask how close your lesion edge sits now.
Not in the sense most people mean. Macular degeneration is a leading cause of vision loss in older adults but does not cause complete blindness, because it damages central vision while side vision remains. Reading and recognizing faces can become difficult, and some people meet the legal definition of blindness on chart testing while still moving around independently. Vision rehabilitation helps keep that remaining sight working.
No treatment restores retinal tissue that has already wasted away, so be skeptical of anything claiming otherwise. What is available are injected medicines that slow how fast the area grows, treatment for the wet form if it develops, supplements considered at the intermediate and advanced stages, and vision rehabilitation. Together those aim to protect the vision you still have.
Often similarly, but not identically. Having atrophy in both eyes is one of the features associated with faster enlargement, and the state of your other eye is a confirmed predictor of pace. In practice one eye is frequently ahead, and the better eye masks changes in the weaker one. That is the best reason to check your eyes one at a time at home.
It can feel that way, and there is a real reason. Chart vision tests one pinpoint of retina, so a patch can enlarge for a long time while acuity looks stable, then change quickly once the center is affected. Reading speed, dim-light vision and glare recovery often fade before the chart does. Describe those difficulties to your doctor, since they shape follow-up more than the acuity number alone.
More Questions About Living With Geographic Atrophy
That is a decision to make with a retina specialist, and there is no universal answer. The trials showed slower lesion growth but no measured benefit on vision over one to two years, and the injections carry risks including new wet macular degeneration and inflammation inside the eye. Reasonable people weigh that differently depending on lesion location and how the other eye is doing. Ask what the goal would be in your case.
Many people can early on, and the honest answer depends on your measured vision and local licensing standards rather than on the diagnosis. Difficulty at night and in glare often comes first, while daytime driving on familiar routes stays comfortable. Have your vision formally assessed, and ask your eye doctor about the rules where you live. Planning a gradual transition beats being surprised by it.
No. Reading, screen time and close work do not accelerate this condition, and there is no evidence that resting your eyes slows it. The damage sits in the support layer under the retina and follows its own course. Use whatever lighting, magnification and font size make reading comfortable, since staying engaged with reading is good for you and does no harm to the retina.
Report it rather than waiting. A sudden bend in straight lines, a new blurred patch or a quick drop in one eye should prompt a call the same week and often sooner, because those suggest the wet form, which is treatable and time-sensitive. Slow changes over months are still worth mentioning, since they may shift your follow-up interval. When in doubt, call.
Bringing a short list turns a rushed visit into a useful one. Consider asking:
- How large is my atrophy now, and how much has it grown since my last scan?
- How close is the edge of the patch to the center of my vision?
- Is my atrophy in one piece or several, and is my other eye affected?
- Am I a reasonable candidate for the injected treatments, and what would we hope to gain?
- Should I be taking an AREDS2 style supplement, given my other health conditions?
- How should I check my eyes at home, and what change should make me call you?
- Ophthalmology (Fleckenstein M, Mitchell P, Freund KB, et al.), literature review (2018). The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
- American Society of Retina Specialists, patient information (2024). Age-Related Macular Degeneration, Dry Forms Including Geographic Atrophy.
- Eye (peer-reviewed review, PMC11751078) (2025). Age-related macular degeneration: natural history revisited in geographic atrophy.
- Ophthalmology Science (peer-reviewed review, PMC10183660) (2023). Geographic Atrophy in Age-Related Macular Degeneration: A Tale of Two Stages.
- Ophthalmology (Domalpally A, Keenan HA, Agron E, et al.), prospective cohort within a randomized trial (2018). Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
- National Eye Institute, National Institutes of Health (2024). Age-Related Macular Degeneration (AMD).
- American Academy of Ophthalmology, Retina/Vitreous Preferred Practice Pattern Panel (2022). Age-Related Macular Degeneration Preferred Practice Pattern (2022 update).
- Ophthalmology (Sunness JS, Gonzalez-Baron J, Applegate CA, et al.), prospectively observed case series of 123 patients (1999). Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration.
- American Journal of Ophthalmology (review of the phase 3 OAKS, DERBY, GATHER1 and GATHER2 randomized trials, PMC11162935) (2024). Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go.